Cooled ThermoTherapy™ (CTT) is a safe, effective, in-office treatment that provides long-term relief from BPH symptoms and urinary obstruction. CTT is appropriate for men experiencing moderate to severe BPH symptoms especially patients who do not want to take daily medications for the rest of their lives, dislike the side effects and ongoing costs of medication or do not want the risks, side effects or high costs of surgery.
How Does it Work?
Cooled ThermoTherapy™ treats BPH by applying microwave energy to the prostate via the transurethral microwave catheter that precisely heats diseased areas while simultaneously circulating cooling fluid in the catheter and protecting the pain-sensitive urethral tissue. This method of circulating cooling fluid through the microwave catheter minimizes patient discomfort and risk of thermal damage to the urethra by maintaining the urethral temperature at less than or equal to 40°C. This effect allows the treatment to be performed in the physician’s office without the need for general anesthesia. Continuous energy delivery allows for a durable and consistent treatment for many men with symptomatic and/or obstructive BPH. The preservation of urethral integrity is a unique feature of Cooled ThermoTherapy™ that defines it as one of the least invasive treatments and limits morbidity.
Cooled ThermoTherapy™ provides significant benefits to you, your practice, and most importantly your patients.
- Relief from the uncomfortable, systematic effects of BPH drugs
- Convenient treatment completed in your office in less than an hour (including preparation and recovery time)
- Minimally invasive treatment which does not require general anesthesia
- Advanced cooling design providing enhanced urethral protection and patient comfort
- Customizable treatment protocols for better patient toleration
- Effective results – clinically significant symptom score and flow rate improvement at five years1
- Durable results – reintervention not necessary in over 90% of patients at five years1
- Low rate of side effects
- Established reimbursement
As with all medical procedures, there are some risks involved with this procedure.2
- Blood in urine
- Clots in urine
- Painful or difficult urination
- Rectal irritation
- Temporary inability to control urination
- Brief inability to achieve or maintain an erection
- Inability to discharge semen in orgasm
For more complete information about the benefits and risks associated with Cooled ThermoTherapy™, please refer to the Cooled ThermoTherapy™ Instructions for Use (6MB PDF).
This procedure was first used in the early ‘90s in FDA-controlled clinical trials. Since then, multiple studies conducted at more than 50 centers worldwide and involving more than 2200 patients have demonstrated significant symptom and urine flow improvements with minimal complications. For a complete overview of the Cooled ThermoTherapy™ clinical data, please go to our Clinical Results page.
Increased Necrosis, Greater Durability4,5
It’s proven. More tissue necrosis equates to a better long-term outcome for patients. Tissue necrosis is a function of time and temperature. 50°C is required to produce tissue necrosis in 60 minutes, higher temperatures produce a larger volume of necrosis in less time. Treatment times at temperatures below injury threshold produce no therapeutic necrosis.3 Cooled ThermoTherapy™ reaches intraprostatic temperatures of 80°C for larger tissue necrosis volume in just a 28.5 minute treatment.
1Mynderse, L., et al, 5 year Results of a Multi-Center Trial of a New Generation Cooled TUMTfor BPH, Journal of Urology, May 2001 2 Data derived from the CTC Advance® Instructions for Use, 250348 Rev D 08/10 3Bishof, et. al., Heat Sensitivity of Human Prostate Tissue: Implications for Thermal Therapy. Poster AUA 2003. 4Larson, T, et al., Detailed Interstitial Temperature Mapping During TUMT Treatment for BPH, Journal of Urology, January 2998. 5Bhowmick, P., et al, In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia, Int. J Hyperthermia, Vol 20, No 4, June 2004, pp 421-39.